Find the right
blood pressure medication
using your DNA.
Hypertension is the leading preventable cause of death in the world.
Geneticure's patented test uses a sample of your DNA to recommend a personalized treatment plan, just for you.
Using the DNA on a cheek swab, Geneticure recommends which hypertension medication(s) may give you the biggest drop in blood pressure:
Fewer prescriptions.
Fewer office visits.
Less trial-and-error.
Your body is unique. Doctors don't know if a blood pressure medication will work until you try it. If it doesn't work, they might add or try another. This trial-and-error costs time and money. Some medications can even make your blood pressure go up.
Geneticure's test looks at 17 genotypes and 11 genes* to determine how your body responds to each medication. Your personalized report helps your doctor prescribe the right medication from the start.
› See the science
Peer-Reviewed Manuscripts
Association of a Multi-Gene Panel with Blood Pressure Medication Success in Patients with Hypertension. Eric M. Snyder, Ryan Sprissler, Micah Johnson, Greg D. Beenken, Timothy Curry, Nicholas Cassuto, and Thomas P. Olson. Hypertension: Open Access. HTOA-103. 2019. DOI: 10.29011/ HTOA-103.100008
Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. Eli F. Kelley, Eric M. Snyder, Nimer Alkhatib, Scott C. Snyder, Ryan Sprissler, Thomas P. Olson, Monica Akre, and Ivo Abraham. Journal of Medical Economics. 2018. Oct 22:1-8. DOI: 10.1080/13696998.2018.1531011. (PMID: 30280614)
The Effect of Genetically Guided Mathematical Prediction and the Blood Pressure Response to Pharmacotherapy in Hypertension Patients. Eli F. Kelley, Thomas P. Olson, Timothy Curry, Ryan Sprissler, and Eric M. Snyder. Clinical Medicine Insights: Cardiology. In press. DOI: 10.1177/1179546819845883. 2019.
Relationship Between a Weighted Multi-Gene Algorithm and Blood Pressure Control in Hypertension. Pamela K. Phelps, Eric M. Snyder, Danielle M. Walla, Jennifer K. Ross, Jerad J. Simmons, Emma K. Bulock, Audrie Ayers, Monica K. Akre, Ryan Sprissler, and Thomas P. Olson. Journal of Clinical Medicine. Feb 28;8(3). 2019. (PMID:30823438)
Data at 36 months for the Symplicity SPYRAL HTN-ON MED pilot. Eric M. Snyder, Ryan Sprissler, Thomas P. Olson. The Lancet. 2022 Aug 13;400(10351):491-492. (PMID: 35964607)
The Importance of Use of Genetics to Guide Hypertension Therapy Using β-Blockade as an Example. Eric M. Snyder, Ryan Sprissler, and Thomas P. Olson. Advances in Molecular Pathology. VOLUME 4, P117-125, NOVEMBER 01, 2021.
ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations. Eric M. Snyder and Bruce D. Johnson. Pharmacogenomics. 2020 Jul;21(10):695-703. DOI: 10.2217/pgs-2020-0048. Epub 2020 Jun 5. (PMID: 32501190)
The importance and challenges of developing a pharmacogenetics test for hypertension. Eric M. Snyder, Eli F. Kelley, Ryan Sprissler, and Thomas P. Olson. Pharmacogenomics. 2019 Jun;20(8):563-566. DOI: 10.2217/pgs-2019-0056. Epub 2019 May 28. (PMID: 31136254)
Presentations at National and International Meetings
Multi-gene Pharmacogenetics and Blood Pressure Control in Patients with Hypertension. MW Johnson, R Sprissler, TP Olson, GW Beenken, and EM Snyder. Presented at the American Society for Health-System Pharmacists, 2016. The FASEB Journal, 30(1) 942.1.
Time to Blood Pressure Control According to Drug Class in Patients with Hypertension. MW Johnson, R Sprissler, TP Olson, GW Beenken, and EM Snyder. Presented at the American Society for Health-System Pharmacists, 2016. The FASEB Journal, 30(1) 941.12.
The Integrative Nature of Pharmacogenetics of Hypertension: Moving Beyond Drug Metabolizing Enzymes. EM Snyder, R Sprissler, and TP Olson. Presented at the Mayo Clinic Center for Individualized Medicine Annual Meeting, October, 2016.
Genes Predicting the Response to Beta-Blockade May Also Influence the Blood Pressure Response to Diuretic Therapy. EM Snyder, R Sprissler, and TP Olson. Presented at the Mayo Clinic Center for Individualized Medicine Annual Meeting, October, 2017.
Influence of genes important in renal sodium handling and the blood pressure response to a diuretic in hypertension. J Ross, D Walla, EM Snyder, R Sprissler, TP Olson, and P Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2017.
Influence of genes involved in the renin-angiotensin-aldosterone system and the blood pressure response to angiotensin receptor blockade in hypertension. D Walla, J Ross, EM Snyder, R Sprissler, TP Olson, and P Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2017.
Pharmacoeconomic Benefit of a Multi-Gene Panel and Blood Pressure Response to Hypertension Therapy. Monica Akre, Eli F. Kelley, Scott C. Snyder, Ryan Sprissler, Thomas P. Olson, and Eric M. Snyder. Presented at the Mayo Clinic Center for Individualized Medicine Annual Meeting. 2018.
Influence of beta-1 and beta-2 adrenergic receptor genotypes on echocardiographic response to selective and non-selective beta-blockade. Jerad J. Simmons, Eric M. Snyder, Audrie Ayres, Emma K. Bulock, Danielle M. Walla, Jennifer K. Ross, Monica Akre, Ryan Sprissler, Thomas P. Olson, Pamela K. Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2018.
Influence of genetic variation of beta-2 adrenergic receptors and blood pressure response to a diuretic. Audrie Ayres, Eric M. Snyder, Danielle M. Walla, Jennifer K. Ross, Jerad J. Simmons, Emma K. Bulock, Monica Akre, Pamela K. Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2018.
Influence of Angiotensin-Converting Enzyme (ACE) Genotypes on Blood Pressure Control and Incidence of Cough in Response to ACE Inhibition. Emma K. Bulock, Pamela K. Phelps, Eric M. Snyder, Danielle M. Walla, Jennifer K. Ross, Jerad J. Simmons, Audrie Ayres, Monica Akre, Laurie Grund, Tammy Ho, Ryan Sprissler, and Thomas P. Olson. Presented at the American Society for Health-System Pharmacists Annual Meeting. 2018.
The influence of beta-1-adrenergic receptor genotype on renal sodium handling and blood pressure response to angiotensin receptor blockers in hypertension patients. Kelley, EF, Phelps, PK, Akre, M, Walla, DM, Ross, JK, Simmons, JJ, Bulok, EK, Ayres, A, & Snyder, EM (2019). FASEB J., 33 1_supplement: 819.5
Relationship between a weighted multi-gene algorithm and blood pressure control in hypertension. Phelps, PK, Kelley, EF, Snyder, EM, Walla, DM, Ross, JK, Simmons, JJ, Bulok, EK, Ayres, A, Akre, MK, Sprissler, R, & Olson, TP (2019). FASEB J., 33 1_supplement: 819.6
Completed and Ongoing Trials
Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension. Clinicaltrials.gov identifier: NCT02524873. Completed.
Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension. Clinicaltrials.gov identifier: NCT02988245. Completed.
Association Between a Genetic Algorithm to Predict Hypertension Therapy and Response to Treatment. Clinicaltrials.gov identifier: NCT03292900. Completed.
Cited Research
Use of Blood Pressure Lowering Drugs in the Prevention of Cardiovascular Disease: Meta-analysis of 147 Randomized Trials in the Context of Expectations from Prospective Epidemiological Studies. MR Law, JK Morris, NJ Wald. BMJ 2009;338:b1665.
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Collins R, Peto R, MacMahon S. Lancet. 1990; 335:827-838.
What our patients say:
How does it work?
-
Order a kit
Purchase a kit online (no prescription required) and we'll get it to your home or office in a few days.
-
Activate your kit
Log on to geneticure.com to activate your kit. You will receive instructions on how to complete the process and access your results. Included in your services, a physician will review your information and follow up with questions if needed. The physician will approve the test, if appropriate. If not approved for any reason, you will receive a full refund for your kit purchase.
-
Swab your cheek
Follow the simple step-by-step instructions included in your kit. Return your sample to Geneticure in the pre-addressed envelope included in your kit.
-
Lab analysis
Once we receive your sample and the independent physician authorization, our CLIA-certified lab will begin to identify the unique markers in your genetic code.
-
Proprietary algorithm
Your unique genetic code is analyzed by our patented software and algorithm, supported by hundreds of peer-reviewed papers as well as our own clinical trial data.
-
Personalized report
Approximately 10-15 business days from when our lab receives the sample, you will receive a personalized report that includes prescription recommendations along with the supporting genetic detail. You will also have the opportunity to discuss your results with a genetic counselor at no additional charge.
-
Talk to your doctor
Share your Geneticure test with your doctor and they may be able to use it to optimize your prescriptions. It is very important that you do not start or stop taking any medications without first consulting your provider.
What's in my report?
Different blood pressure treatments target different systems in your body. Your DNA can predict which system is most likely to respond to treatment. Your Geneticure report describes the responsiveness of 3 of your body's main organ systems:
-
Cardiac system
Controls how hard and fast your heart beats
-
Vascular system
Controls the tightening of blood vessels
-
Renal system
Controls the absorption of sodium and water in your kidneys
Who is Geneticure?
We're a team of hypertension expert scientists and doctors based in Rochester, Minnesota, home of the Mayo Clinic — which is also an investor in Geneticure. For 10 years we've put science and innovation to work, taking personalized medicine to the next level, unmatched in the world of pharmacogenomics. Contact us.
Notable investors:
Our team:
-
Scott Snyder
CEO
Scott spent 10 years in entrepreneurial roles leading Target Corporation businesses in Minneapolis; most recently as director of a strategic advisory group for over $10 Billion of consumer categories including OTC pharmacy. Scott's experience in consumer insights, analytics, digital marketing, and finance along with his longtime passion for investments in developmental stage biotechnology, led to his co-founding of Geneticure with Eric Snyder, Ryan Sprissler, and Tom Olson.
-
Eric Snyder
COO
Dr. Snyder completed his PhD at the University of Minnesota and performed his research training at Mayo Clinic as a pre-doctoral fellow and post-doctoral fellow in Cardiovascular Diseases with a second post-doctoral fellowship in Nephrology and Hypertension. He was an assistant professor in the College of Pharmacy at the University of Arizona and then moved on to the University of Minnesota before co-founding Geneticure.
-
Ryan Sprissler, PhD
CSO
Dr. Sprissler is a founding member of the Center for Applied Genetics and Genomic Medicine and Lead Scientist managing the University of Arizona Genetics Core facility specializing in cutting edge genomic technology. An industry pioneer, he has leveraged several partnerships fueling the high growth industry of genomic testing. With 15 years of experience in genetic assay design/testing he is a current member of the Association for Bioresource Facilities (ABRF), the Association for Laboratory Automation (ALA) & the American Association for the Advancement of Science (AAAS).
-
Thomas Olson, PhD
CCO
Dr. Olson is an Associate Professor of Medicine and Science and Consultant in the Department of Cardiovascular Medicine at Mayo Clinic where he sees patients in the Division of Preventive Cardiology. He is the Director of the Clinical Integrative Physiology Research Laboratory which is funded by the National Institutes of Health, American Heart Association, and Industry.
-
Timothy Curry, MD, PhD
Medical Director
Dr. Curry has lead large clinical pharmacogenomic implementation projects and is a leader in pharmacogenomic education. He is the Director of the Education Program of the Mayo Clinic Center for Individualized Medicine as well as the Vice Chair of Practice for the Department of Anesthesiology and Perioperative Medicine, also at Mayo Clinic. He is also an integrative physiologist with special expertise in cardiopulmonary and neural physiology.
-
Bruce Johnson, PhD
Board of Advisors
Dr. Johnson is a Professor of Medicine and Physiology at Mayo Clinic, Rochester, Minnesota. Dr. Johnson has an established, NIH-funded laboratory to study genetics and cardiorespiratory function in patients with heart failure as well as grants from NSF and DOD focused on environmental physiology. Dr. Johnson received his BA from Pacific Lutheran University, Masters from St. Cloud State University and PhD in Respiratory Physiology and Biodynamics from the University of Wisconsin, Madison. Dr. Johnson completed a fellowship through the Mayo Graduate School of Medicine, Mayo Clinic College of Medicine and is a Consultant in the Division of Cardiovascular Diseases.
-
Dr. Bonny Lewis Van, PhD
Laboratory Director
Dr. Lewis Van completed her award-winning clinical laboratory fellowship at the University of Louisville, with an emphasis on pharmacogenetics. She has been on the faculty of Virginia Commonwealth University with appointments in Pharmacy, Pathology and Anesthesiology as well as being a member of the Bioinformatics faculty. Bonny helped to create a nation-wide pharmacogenetic company, and currently holds several leadership positions in the American Association for Clinical Chemistry (AACC), American Association of Bioanalysts (AAB) and the American Board of Bioanalysis (ABB) and is a Clinical Laboratory Informatics Lead for J Michael Consulting.
-
David Herbert
EVP of Strategy
David spent over 20 years in leadership roles at Mayo Clinic, including Chief Administrative Officer of Mayo Medical Laboratories; Chair of Mayo Clinic Global Business Solutions; and Director of Technology Commercialization at Mayo Medical Ventures. David is an emeritus member of the Mayo Clinic staff, a board member and treasurer of the national Myotonic Dystrophy Foundation, and chair of the Southeast Minnesota Capital Fund.
-
Don Wright
Senior Advisor
Don Wright spent the past decade growing Assurex Health from technology invented at Mayo Clinic and Cincinnati Children's Hospital Medical Center to a company of almost 500 employees serving over 500,000 people with mental health conditions. Assurex Health was acquired in 2016 by Myriad Genetics allowing Don to use his more than 25 years of experience in the informatics, product development, operations and life sciences fields, to assisting others turn their ideas into hyper-growth companies.
-
Carl Jepsen
Director of Operations
Carl has 18 years of banking, finance and commercial real estate experience. Prior to joining Geneticure, he most recently held the position of a Business Banking Relationship Manager. In that role, he consulted with clients and prospective clients, in all stages of growth, regarding process management, transition, and business strategies.
-
Robin Thomas
Staff Software Engineer
Robin has implemented new design systems at Google, managed merchant Bitcoin adoption for Coinbase, and lead machine learning initiatives at Best Buy's digital headquarters. He loves teaching code as much as writing it, and was among the highest-rated instructors of General Assembly's Web Development Immersive. He encourages you to try the Konami Code on this site.
- See our full team ›
